Published in Comput Math Methods Med on September 04, 2012
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opin Biol Ther (2016) 0.85
Autoradiography imaging in targeted alpha therapy with Timepix detector. Comput Math Methods Med (2015) 0.75
In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy. PLoS One (2017) 0.75
Tumor therapy with targeted atomic nanogenerators. Science (2001) 2.48
First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res (2005) 2.04
Targeted alpha particle immunotherapy for myeloid leukemia. Blood (2002) 1.99
Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med (1998) 1.67
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med (2010) 1.61
Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res (2004) 1.38
Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science (1988) 1.32
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res (2010) 1.17
Review of clinical radioimmunotherapy. Expert Rev Anticancer Ther (2006) 1.15
Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging (2004) 1.14
Radioimmunotherapy with alpha-particle emitters: microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei. Radiat Res (2001) 1.12
Energy deposition stochastics and track structure: what about the target? Radiat Prot Dosimetry (2007) 1.10
Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med (2008) 1.01
Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi. Br J Cancer (1999) 1.00
Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells. Radiat Res (1999) 0.99
A model of cell inactivation by alpha-particle internal emitters. Radiat Res (1993) 0.99
Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther (2007) 0.98
Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. J Nucl Med (2001) 0.95
Radionuclide carriers for targeting of cancer. Int J Nanomedicine (2008) 0.94
Clinical trials of targeted alpha therapy for cancer. Rev Recent Clin Trials (2008) 0.93
Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys Med Biol (2011) 0.91
Alpha-particles for targeted therapy. Adv Drug Deliv Rev (2008) 0.91
Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer. Phys Med Biol (2007) 0.85
Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. I. Presentation and validation of a microdosimetric model. Radiat Res (2009) 0.84
Microdosimetric concepts in radioimmunotherapy. Med Phys (1993) 0.84
A comparison of cellular irradiation techniques with alpha particles using the Geant4 Monte Carlo simulation toolkit. Radiat Prot Dosimetry (2006) 0.83
A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy. Med Phys (2011) 0.83
Microdosimetry of internal sources. Radiat Res (1977) 0.83
Monte Carlo dosimetry for targeted irradiation of individual cells using a microbeam facility. Radiat Prot Dosimetry (2009) 0.81
Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesis. Med Phys (2010) 0.81
A database of frequency distributions of energy depositions in small-size targets by electrons and ions. Radiat Prot Dosimetry (2010) 0.81
Monte Carlo calculation of the maximum therapeutic gain of tumor antivascular alpha therapy. Med Phys (2012) 0.80
Comparison of different classes of radionuclides for potential use in radioimmunotherapy. Hell J Nucl Med (2007) 0.79
Analytic microdosimetry for radioimmunotherapeutic alpha emitters. Med Phys (1993) 0.78
Can α-radioimmunotherapy increase efficacy for the systemic control of cancer? Immunotherapy (2011) 0.78
Dosimetric framework for therapeutic alpha-particle emitters. J Nucl Med (1997) 0.78
Panel discussion: Do non-targeted effects impact the relation between microdosimetry and risk? Radiat Prot Dosimetry (2010) 0.77
Tissue equivalence correction for silicon microdosimetry detectors in boron neutron capture therapy. Med Phys (1998) 0.77
Radioimmunotherapy: optimizing delivery to solid tumors. Ther Deliv (2011) 0.77
Dosimetry and microdosimetry of targeted radiotherapy. Curr Pharm Des (2000) 0.77
The survival of monolayers of cells growing in clusters irradiated by 211At appended to the cell surfaces. Radiat Res (1999) 0.77
Performance of silicon microdosimetry detectors in boron neutron capture therapy. Radiat Res (1999) 0.76
Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model. Cancer Biol Ther (2007) 1.85
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med (2010) 1.61
Recurrent and injurious falls in the year following hip fracture: a prospective study of incidence and risk factors from the Sarcopenia and Hip Fracture study. J Gerontol A Biol Sci Med Sci (2009) 1.26
MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis (2006) 1.11
Estimation of thigh muscle cross-sectional area by dual-energy X-ray absorptiometry in frail elderly patients. Am J Clin Nutr (2007) 1.04
Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer. Contrast Media Mol Imaging (2013) 1.04
Methodology and baseline characteristics for the Sarcopenia and Hip Fracture study: a 5-year prospective study. J Gerontol A Biol Sci Med Sci (2009) 1.01
Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas (2008) 0.99
Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther (2007) 0.98
Optimizing radioimmunoconjugate delivery in the treatment of solid tumor. Cancer Treat Rev (2012) 0.91
Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer. Clin Exp Metastasis (2006) 0.91
In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595. Cancer Biol Ther (2005) 0.90
Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction. J Gastroenterol Hepatol (2005) 0.88
Preoperative body composition is influenced by the stage of operable pancreatic adenocarcinoma but does not predict survival after Whipple's procedure. HPB (Oxford) (2010) 0.87
Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters. Cancer Lett (2005) 0.87
Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer. Phys Med Biol (2007) 0.85
Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugates. Clin Cancer Res (2009) 0.85
Tissue equivalency of phantom materials for neutron dosimetry in proton therapy. Med Phys (2009) 0.85
Pharmacokinetics and toxicity of (213)Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer. Cancer Biol Ther (2007) 0.85
Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugate. Cancer Lett (2004) 0.85
Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates. Int J Radiat Oncol Biol Phys (2004) 0.84
An unusual case of radioactive seed migration to the vertebral venous plexus and renal artery with nerve root compromise. Brachytherapy (2010) 0.84
Validity of subjective global assessment as a nutritional marker in end-stage renal disease. Am J Kidney Dis (2002) 0.82
Evaluating the effect of ultrasmall superparamagnetic iron oxide nanoparticles for a long-term magnetic cell labeling. J Med Phys (2013) 0.81
In silico nanodosimetry: new insights into nontargeted biological responses to radiation. Comput Math Methods Med (2012) 0.81
Monte Carlo calculation of the maximum therapeutic gain of tumor antivascular alpha therapy. Med Phys (2012) 0.80
Estimated background doses of [67Ga]-DTPA-USPIO in normal Balb/c mice as a potential therapeutic agent for liver and spleen cancers. Nucl Med Commun (2013) 0.79
Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates. Prostate (2006) 0.79
In vivo studies of pharmacokinetics and efficacy of Bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27. Cancer Biol Ther (2005) 0.79
The cytokinesis-block micronucleus assay as a biological dosimeter for targeted alpha therapy. Phys Med Biol (2007) 0.79
A comparison of X-ray and proton beam low energy secondary electron track structures using the low energy models of Geant4. Int J Radiat Biol (2012) 0.79
Can α-radioimmunotherapy increase efficacy for the systemic control of cancer? Immunotherapy (2011) 0.78
In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells. Invest Ophthalmol Vis Sci (2005) 0.78
Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205/Bismuth-206. Cancer Biol Ther (2008) 0.78
Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model. Cancer Biol Ther (2006) 0.78
Cytotoxicity of breast cancer cells overexpressing HER2/neu by 213Bi-Herceptin radioimmunoconjugate. Cancer Lett (2005) 0.77
Effect of a static magnetic field on nanodosimetric quantities in a DNA volume. Int J Radiat Biol (2011) 0.76
Targeted alpha-therapy for control of micrometastatic prostate cancer. Expert Rev Anticancer Ther (2004) 0.76
Habitual physical activity, anabolic hormones, and potassium content of fat-free mass in postmenopausal women. Am J Clin Nutr (2002) 0.75
Addendum to: Basic immunology of antibody targeted radiotherapy: in regard to Wong (Int J Radiat Oncol Biol Phys 2006;66: S8-S14). Int J Radiat Oncol Biol Phys (2007) 0.75
On the use of a convolution-superposition algorithm for plan checking in lung stereotactic body radiation therapy. J Appl Clin Med Phys (2016) 0.75
Next-generation therapy for residual prostate cancer. Immunotherapy (2013) 0.75
Correction factors to convert microdosimetry measurements in silicon to tissue in (12)C ion therapy. Phys Med Biol (2017) 0.75
Cyclotron and linac production of Ac-225. Appl Radiat Isot (2008) 0.75